Adhera Therapeutics, Inc. (ATRX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 1.61 Million USD | 140.06% |
| 2021 | 674 Thousand USD | -66.91% |
| 2020 | 2.03 Million USD | -79.72% |
| 2019 | 10.04 Million USD | -1.89% |
| 2018 | 10.23 Million USD | 68.07% |
| 2017 | 6.09 Million USD | 703.8% |
| 2016 | 757.73 Thousand USD | -83.77% |
| 2015 | 4.66 Million USD | 16.14% |
| 2014 | 4.02 Million USD | 62.1% |
| 2013 | 2.48 Million USD | -76.2% |
| 2012 | 10.41 Million USD | -47.4% |
| 2011 | 19.8 Million USD | -30.41% |
| 2010 | 28.46 Million USD | 13.99% |
| 2009 | 24.97 Million USD | -50.44% |
| 2008 | 50.38 Million USD | -30.56% |
| 2007 | 72.56 Million USD | 26.31% |
| 2006 | 57.45 Million USD | 39.35% |
| 2005 | 41.22 Million USD | 37.06% |
| 2004 | 30.08 Million USD | 19.59% |
| 2003 | 25.15 Million USD | 16.33% |
| 2002 | 21.62 Million USD | 85.54% |
| 2001 | 11.65 Million USD | -21.52% |
| 2000 | 14.85 Million USD | 5.32% |
| 1999 | 14.1 Million USD | 38.24% |
| 1998 | 10.2 Million USD | 3.03% |
| 1997 | 9.9 Million USD | 0.0% |
| 1996 | - USD | -100.0% |
| 1995 | 3 Million USD | 233.33% |
| 1994 | 900 Thousand USD | -6.25% |
| 1993 | 960 Thousand USD | 52.38% |
| 1992 | 630 Thousand USD | -47.93% |
| 1991 | 1.21 Million USD | -21.94% |
| 1990 | 1.55 Million USD | 22.05% |
| 1989 | 1.27 Million USD | -13.01% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q1 | 353 Thousand USD | -2.22% |
| 2023 Q3 | 269.49 Thousand USD | -8.95% |
| 2023 Q2 | 296 Thousand USD | -16.15% |
| 2022 Q4 | 361 Thousand USD | -34.12% |
| 2022 Q1 | 260 Thousand USD | 28.08% |
| 2022 Q2 | 449 Thousand USD | 72.69% |
| 2022 Q3 | 548 Thousand USD | 22.05% |
| 2022 FY | 1.61 Million USD | 140.06% |
| 2021 Q1 | 110 Thousand USD | -32.93% |
| 2021 Q3 | 232 Thousand USD | 79.84% |
| 2021 Q2 | 129 Thousand USD | 17.27% |
| 2021 FY | 674 Thousand USD | -66.91% |
| 2021 Q4 | 203 Thousand USD | -12.5% |
| 2020 Q1 | 1.32 Million USD | -50.38% |
| 2020 FY | 2.03 Million USD | -79.72% |
| 2020 Q2 | 356 Thousand USD | -73.09% |
| 2020 Q3 | 194 Thousand USD | -45.51% |
| 2020 Q4 | 164 Thousand USD | -15.46% |
| 2019 Q1 | 2.44 Million USD | 11.2% |
| 2019 Q3 | 2.16 Million USD | -21.53% |
| 2019 FY | 10.04 Million USD | -1.89% |
| 2019 Q4 | 2.66 Million USD | 22.91% |
| 2019 Q2 | 2.76 Million USD | 13.09% |
| 2018 Q2 | 3.76 Million USD | 209.78% |
| 2018 Q4 | 2.19 Million USD | -28.02% |
| 2018 Q3 | 3.05 Million USD | -18.96% |
| 2018 Q1 | 1.21 Million USD | -61.24% |
| 2018 FY | 10.23 Million USD | 68.07% |
| 2017 Q2 | 948.91 Thousand USD | -1.9% |
| 2017 FY | 6.09 Million USD | 703.8% |
| 2017 Q4 | 3.13 Million USD | 202.94% |
| 2017 Q1 | 967.25 Thousand USD | 166.93% |
| 2017 Q3 | 1.03 Million USD | 9.18% |
| 2016 Q1 | 1.25 Million USD | 52.56% |
| 2016 Q4 | -1.44 Million USD | -344.55% |
| 2016 Q3 | 591 Thousand USD | 63.71% |
| 2016 FY | 757.73 Thousand USD | -83.77% |
| 2016 Q2 | 361 Thousand USD | -71.14% |
| 2015 Q2 | 1.42 Million USD | 8.14% |
| 2015 FY | 4.66 Million USD | 16.14% |
| 2015 Q3 | 1.11 Million USD | -21.8% |
| 2015 Q1 | 1.31 Million USD | 11.54% |
| 2015 Q4 | 820 Thousand USD | -26.26% |
| 2014 FY | 4.02 Million USD | 62.1% |
| 2014 Q4 | 1.17 Million USD | -26.63% |
| 2014 Q3 | 1.6 Million USD | 139.49% |
| 2014 Q2 | 671 Thousand USD | 19.18% |
| 2014 Q1 | 563 Thousand USD | -42.37% |
| 2013 Q2 | 501 Thousand USD | 53.68% |
| 2013 FY | 2.48 Million USD | -76.2% |
| 2013 Q4 | 977 Thousand USD | 44.53% |
| 2013 Q3 | 676 Thousand USD | 34.93% |
| 2013 Q1 | 326 Thousand USD | -87.5% |
| 2012 Q1 | 4.27 Million USD | 1.16% |
| 2012 FY | 10.41 Million USD | -47.4% |
| 2012 Q4 | 2.6 Million USD | 92.97% |
| 2012 Q3 | 1.35 Million USD | -38.17% |
| 2012 Q2 | 2.18 Million USD | -48.9% |
| 2011 FY | 19.8 Million USD | -30.41% |
| 2011 Q1 | 5.25 Million USD | 10.24% |
| 2011 Q2 | 5.52 Million USD | 5.08% |
| 2011 Q3 | 4.8 Million USD | -12.92% |
| 2011 Q4 | 4.22 Million USD | -12.07% |
| 2010 Q4 | 4.76 Million USD | -58.41% |
| 2010 Q3 | 11.45 Million USD | 88.27% |
| 2010 Q2 | 6.08 Million USD | -1.19% |
| 2010 FY | 28.46 Million USD | 13.99% |
| 2010 Q1 | 6.15 Million USD | 14.91% |
| 2009 Q4 | 5.35 Million USD | -21.16% |
| 2009 Q1 | 6.22 Million USD | -49.15% |
| 2009 Q3 | 6.79 Million USD | 3.13% |
| 2009 Q2 | 6.59 Million USD | 5.91% |
| 2009 FY | 24.97 Million USD | -50.44% |
| 2008 Q3 | 10.1 Million USD | -17.97% |
| 2008 Q1 | 15.72 Million USD | -15.74% |
| 2008 FY | 50.38 Million USD | -30.56% |
| 2008 Q2 | 12.31 Million USD | -21.68% |
| 2008 Q4 | 12.23 Million USD | 21.1% |
| 2007 Q4 | 18.66 Million USD | -1.05% |
| 2007 Q3 | 18.86 Million USD | 5.51% |
| 2007 FY | 72.56 Million USD | 26.31% |
| 2007 Q2 | 17.87 Million USD | 4.2% |
| 2007 Q1 | 17.15 Million USD | 8.1% |
| 2006 FY | 57.45 Million USD | 39.35% |
| 2006 Q4 | 15.87 Million USD | 13.95% |
| 2006 Q1 | 15.14 Million USD | 40.8% |
| 2006 Q2 | 12.5 Million USD | -17.46% |
| 2006 Q3 | 13.93 Million USD | 11.42% |
| 2005 FY | 41.22 Million USD | 37.06% |
| 2005 Q3 | 10.46 Million USD | 1.66% |
| 2005 Q4 | 10.75 Million USD | 2.82% |
| 2005 Q2 | 10.29 Million USD | 5.93% |
| 2005 Q1 | 9.71 Million USD | 33.02% |
| 2004 FY | 30.08 Million USD | 19.59% |
| 2004 Q4 | 7.3 Million USD | -3.95% |
| 2004 Q3 | 7.6 Million USD | 1.59% |
| 2004 Q2 | 7.48 Million USD | -2.63% |
| 2004 Q1 | 7.68 Million USD | 13.36% |
| 2003 Q4 | 6.78 Million USD | 3.2% |
| 2003 FY | 25.15 Million USD | 16.33% |
| 2003 Q1 | 5 Million USD | -25.56% |
| 2003 Q3 | 6.57 Million USD | -3.32% |
| 2003 Q2 | 6.79 Million USD | 35.83% |
| 2002 Q1 | 4.3 Million USD | 32.68% |
| 2002 Q2 | 5.13 Million USD | 19.08% |
| 2002 Q3 | 5.46 Million USD | 6.49% |
| 2002 Q4 | 6.72 Million USD | 23.05% |
| 2002 FY | 21.62 Million USD | 85.54% |
| 2001 FY | 11.65 Million USD | -21.52% |
| 2001 Q2 | 2.79 Million USD | -13.33% |
| 2001 Q4 | 3.24 Million USD | 25.22% |
| 2001 Q3 | 2.59 Million USD | -7.26% |
| 2001 Q1 | 3.22 Million USD | -36.55% |
| 2000 FY | 14.85 Million USD | 5.32% |
| 2000 Q2 | 3.32 Million USD | -1.31% |
| 2000 Q1 | 3.36 Million USD | -32.7% |
| 2000 Q3 | 3.08 Million USD | -7.26% |
| 2000 Q4 | 5.08 Million USD | 65.06% |
| 1999 Q4 | 5 Million USD | 66.67% |
| 1999 Q1 | 3.9 Million USD | 39.29% |
| 1999 Q2 | 2.8 Million USD | -28.21% |
| 1999 Q3 | 3 Million USD | 7.14% |
| 1999 FY | 14.1 Million USD | 38.24% |
| 1998 Q3 | 2.7 Million USD | -3.57% |
| 1998 Q2 | 2.8 Million USD | 33.33% |
| 1998 Q1 | 2.1 Million USD | -32.26% |
| 1998 Q4 | 2.8 Million USD | 3.7% |
| 1998 FY | 10.2 Million USD | 3.03% |
| 1997 Q3 | 2.8 Million USD | 16.67% |
| 1997 FY | 9.9 Million USD | 0.0% |
| 1997 Q4 | 3.1 Million USD | 10.71% |
| 1997 Q2 | 2.4 Million USD | 60.0% |
| 1997 Q1 | 1.5 Million USD | 0.0% |
| 1996 Q2 | 1.2 Million USD | 33.33% |
| 1996 Q1 | 900 Thousand USD | 0.0% |
| 1996 Q3 | 1.1 Million USD | -8.33% |
| 1996 FY | - USD | -100.0% |
| 1995 Q2 | 1 Million USD | 42.86% |
| 1995 Q1 | 700 Thousand USD | 0.0% |
| 1995 Q3 | 900 Thousand USD | -10.0% |
| 1995 Q4 | 900 Thousand USD | 0.0% |
| 1995 FY | 3 Million USD | 233.33% |
| 1994 Q2 | 300 Thousand USD | 0.0% |
| 1994 Q3 | 600 Thousand USD | 100.0% |
| 1994 FY | 900 Thousand USD | -6.25% |
| 1994 Q4 | 700 Thousand USD | 16.67% |
| 1994 Q1 | 300 Thousand USD | 200.0% |
| 1993 Q3 | 300 Thousand USD | -30.23% |
| 1993 FY | 960 Thousand USD | 52.38% |
| 1993 Q4 | 100 Thousand USD | -66.67% |
| 1993 Q2 | 430 Thousand USD | 0.0% |
| 1992 FY | 630 Thousand USD | -47.93% |
| 1991 FY | 1.21 Million USD | -21.94% |
| 1990 FY | 1.55 Million USD | 22.05% |
| 1989 FY | 1.27 Million USD | -13.01% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -21.159% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 67.91% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 94.525% |
| Nascent Biotech, Inc. | 2.22 Million USD | 27.44% |
| Rebus Holdings, Inc. | 664 Thousand USD | -143.675% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 95.657% |
| Qrons Inc. | 643.67 Thousand USD | -151.368% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -315.334% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 97.183% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -289.43% |
| Skye Bioscience, Inc. | 13.54 Million USD | 88.057% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 98.136% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 67.1% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -518.204% |
| SQZ Biotechnologies Company | 85.61 Million USD | 98.11% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 44.518% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -7.73% |
| Mesoblast Limited | 5.9 Million USD | 72.586% |
| Marizyme, Inc. | 19.23 Million USD | 91.59% |
| Genus plc | 147.7 Million USD | 98.905% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 81.57% |
| Pharming Group N.V. | 225.49 Million USD | 99.282% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 21.023% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -20.607% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 80.597% |
| ContraFect Corporation | 56.88 Million USD | 97.156% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 63.3% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -9.417% |
| IMV Inc. | 37.7 Million USD | 95.709% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 42.015% |
| MultiCell Technologies, Inc. | 567.42 USD | -285050.33% |
| ONE Bio Corp. | 6.44 Million USD | 74.891% |
| Accustem Sciences Inc. | 3.74 Million USD | 56.812% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 98.117% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -204.157% |
| Q BioMed Inc. | 3.43 Million USD | 52.919% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 93.453% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 38.421% |
| Biomind Labs Inc. | 994.18 Thousand USD | -62.747% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 98.371% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 8.051% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 75.916% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 13.215% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 6572.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 89.894% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 11.83% |
| GB Sciences, Inc. | 1.42 Million USD | -13.903% |
| Alpha Cognition Inc. | 9.7 Million USD | 83.329% |
| HST Global, Inc. | 140.9 Thousand USD | -1048.275% |
| CSL Limited | 3.44 Billion USD | 99.953% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -43.834% |
| Halberd Corporation | 74.84 Thousand USD | -2061.888% |
| Enzolytics Inc. | 2.17 Million USD | 25.763% |
| Agentix Corp. | 1.37 Million USD | -17.951% |
| Resverlogix Corp. | 12.71 Million USD | 87.272% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 55.68% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.894% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -54.981% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 32.722% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -2.447% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 52.481% |
| AVAX Technologies, Inc. | 7.31 Million USD | 77.867% |
| Zenith Capital Corp. | 8.94 Million USD | 81.908% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.804% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -9187.641% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 34.102% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -843.391% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 15.769% |
| Kadimastem Ltd | 2.41 Million USD | 32.866% |
| Helix BioMedix, Inc. | 1.97 Million USD | 17.953% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 85.111% |
| BioStem Technologies, Inc. | 22.97 Million USD | 92.958% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -791.534% |
| LadRx Corporation | 3.81 Million USD | 57.553% |
| Cell Source, Inc. | 4.32 Million USD | 62.593% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -75.201% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -75.201% |
| NovAccess Global Inc. | 2.46 Million USD | 34.408% |
| Affymax, Inc. | 39.38 Million USD | 95.892% |
| Itoco Inc. | 919.14 Thousand USD | -76.034% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 61.825% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -44.593% |
| Mobile Lads Corp. | 554.54 Thousand USD | -191.77% |
| CytoDyn Inc. | 18.05 Million USD | 91.04% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -6328.543% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -635.194% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -13.96% |
| SYBLEU INC | 160.87 Thousand USD | -905.744% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 10.919% |
| International Stem Cell Corporation | 5.27 Million USD | 69.304% |
| Bioxytran, Inc. | 3.82 Million USD | 57.646% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -2973.591% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -7853.596% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 95.539% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -119.886% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 47.991% |
| Neutra Corp. | 243.82 Thousand USD | -563.602% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 90.732% |
| PureTech Health plc | 144.59 Million USD | 98.881% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 92.103% |
| IXICO plc | 4.7 Million USD | 65.626% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 81.607% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 98.626% |
| CSL Limited | 3.89 Billion USD | 99.958% |
| Cellectis S.A. | 97.32 Million USD | 98.337% |